Quantcast

Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83


Shutterstock photo

The Relative Strength ( RS ) Rating for Accelerate Diagnostics ( AXDX ) jumped into a new percentile Friday, with an increase from 71 to 83.

[ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

Accelerate Diagnostics is building a cup with handle with a 30.20 buy point . See if the stock can break out in volume at least 40% higher than normal.

The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 8%. Revenue rose from 3,400% to 4,050%.

The company earns the No. 43 rank among its peers in the Medical-Products industry group. Align Technology ( ALGN ), Abiomed ( ABMD ) and Edwards Lifesciences ( EW ) are among the top 5 highly rated stocks within the group.

RELATED:

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: RS , AXDX , ALGN , ABMD , EW


More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing








Research Brokers before you trade

Want to trade FX?